Is there a role for post-operative chemoradiation therapy in fully resected, margin-negative T3N1 NSCLC?

I assume you're talking about T3 for chest wall invasion, and I think the answer is probably no routine role for RT for this individual risk factor. If you look at surgical series, invasion of the chest wall IS a risk factor for both positive surgical margins, and local recurrence. But if you limit yourself to patients with T3 who undergo en bloc resection with negative margins, the local failure rate was no higher than you would expect for tumors without chest wall invasion, and was not decreased by RT (Gould et al, Red Journal 99 for example).

As for N1 patient, I think the majority of the evidence suggests that we should not be routinely treating these either. Chris Kelsey has done some good work demonstrating increased recurrence risk af...

I agree with @Dr. First Last.

While survival in resected lung cancer is dominently driven by nodal status, the utility of PORT is murky.

The principal issue appears to be a tradeoff between the appealing feature of RT in reducing local-regional recurrence, contrasted with the rather compelling data that RT to the thorax, particularly when delivered to large volumes, high doses, high doses/fx, and antiquated equipment (vis a vis the PORT meta-analysis), contributes to difficult-to-ascertain toxicity (likely cardiopulmonary) which decrease overall survival.

The surge of recent data on N2 disease from the aforementioned analyses (blatant advertisement inserted here - http://www.ncbi.nlm.nih.gov/pubmed/25667283) demonstrates a likely survival adva...